

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Yidu Tech Inc.**  
**醫渡科技有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2158)**

## **CHANGE OF EXECUTIVE DIRECTOR**

This announcement is made by Yidu Tech Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of the Company hereby announces that Dr. Xie Li (“**Dr. Xie**”) has been appointed as an executive Director with effect from 27 January 2025.

The biographical details of Dr. Xie are set out below:

Dr. Xie Li, MD, PhD, aged 48, has served as the Head of Innovative Medicine and Real-World Evidence Department at Tianjin Happy Life Technology Co., Ltd., an affiliated company of the Company, since May 2022.

Dr. Xie has nearly ten years of experience as a clinical doctor and more than ten years of working experience in the medical affairs, health economics, and outcomes research departments at top ten multinational pharmaceutical companies, and serves as a member of the Professional Committee on Pharmaceutical Policy and Evaluation of the National Association of Health Industry and Enterprise Management (全國衛生產業企業管理協會醫藥政策與評價專業委員會) and an external expert at the China-Australia Joint Research Center for Infectious Diseases jointly established by Monash University in Australia and Xi’an Jiaotong University Health Science Centre (西安交通大學醫學部). She has supported the launch of the most successful pharmaceutical products in China and several first-in-class drugs, as well as market access work including medical insurance negotiations, centralized procurement, and commercial insurance. Dr. Xie has extensive industry experience in the medical, pharmaceutical, and health insurance fields. Her major research areas focus on real-world studies and health economics research, collaboration with research institutes and pharmaceutical and medical device companies to promote the application of AI and big data in healthcare and health insurance.

Dr. Xie was the awardee of the scientific and technological second prize of Shaanxi Province and the recipient of multiple research grants. She collaborated with research institutions including Shanghai Fudan University, Peking University, Capital Medical University, the Health Development Research Center of the National Health Commission (衛健委衛發中心), and the Shanghai Health Development Research Center (上海衛發中心) and jointly published the “Research Report on the Value Evaluation and Practical Application of High-Value Medical Consumables (《高值醫用耗材價值評估與實踐應用研究報告》)”, which is the most complete evaluation system of high-value medical consumables with the most comprehensive value dimension in China, and has published over 20 papers in renowned academic journals and conferences, including the Journal of Hepatology, Hepatology, JAMA Network Open, and ISPOR. Dr. Xie obtained her Doctor of Medicine degree from Xi’an Jiaotong University in December 2019.

Dr. Xie has entered into a service contract with the Company for an initial term of three years which is subject to retirement as and when required under the articles of association of the Company and will be automatically renewed for successive periods of three years until terminated in accordance with the terms of the service contract. Dr. Xie is entitled to receive a director’s fee of RMB160,000 per annum from the Group for services provided to the Company in her capacity as an executive Director. Dr. Xie’s remuneration may include share awards, which she may from time to time be entitled. Such remuneration/emoluments will be reviewed annually by the Board and the remuneration committee of the Board and she is also entitled to a discretionary bonus with reference to her performance and the operating results of the Group.

Dr. Xie is interested in an aggregate of 371,900 Shares of the Company, comprising 49,225 Shares held by her, and 322,675 Shares underlying awards granted to her under the post-IPO share award scheme approved and adopted by the Company on 28 December 2020 and amended on 28 September 2023.

Save as disclosed above, as at the date of this announcement:

- (i) Dr. Xie did not hold any directorship in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas or other major appointments and professional qualifications;
- (ii) Dr. Xie did not have any interest in the Shares or underlying Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong);
- (iii) Dr. Xie did not hold any other position in the Company or its subsidiaries or have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company (as defined under the Listing Rules); and
- (iv) there was no other information in relation to Dr. Xie’s appointment that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules or any matter that need to be brought to the attention of the shareholders of the Company.

## **RESIGNATION OF EXECUTIVE DIRECTOR**

The Board of the Company hereby announces that Dr. Yan Jun (“**Dr. Yan**”) has tendered his resignation as an executive Director the Company, with effect from 27 January 2025, to focus on the Company’s technology research and development work. Dr. Yan has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company. Dr. Yan will remain as the Chief Technology Officer of the Company and the Chief AI Scientist of the Group.

The Board would like to express its warmest welcome to Dr. Xie on her appointment and its gratitude to Dr. Yan for his valuable contribution to the Company during his tenure of office.

By order of the Board  
**Yidu Tech Inc.**  
**Gong Yingying**  
*Executive Director and Chairlady*

Hong Kong, 27 January 2025

*As at the date of this announcement, the executive Directors are Ms. Gong Yingying, Mr. Xu Jiming, Ms. Feng Xiaoying, and Dr. Xie Li; the non-executive Director is Mr. Zeng Ming; and the independent non-executive Directors are Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi.*